Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment for Advanced Hepatocellular Carcinoma
Findings from the CheckMate 459 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular Lymphoma
Findings from the ELARA study
EMA Recommends Extension of Indications for Lorlatinib
New indication concerns the treatment of adult patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor
EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the Treatment of Urothelial Cancer
An antibody drug conjugate induces cytotoxicity in cancer cells by binding to the nectin-4
FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions
An optical imaging agent that targets folate receptor is an adjunct for interoperative identification of malignant lesions in adult patients with ovarian cancer
A Remarkable Group of Patients with Haematological Disorders with No or Low Immune Response After Second COVID-19 Vaccine Dose
The rate of negative antibody results highest among patients with lymphoid neoplasms
Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated Solid Malignancies
Updated results of the Vax-On study favour the third vaccine dose for actively treated patients with cancer
Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events
Findings from an exploratory subgroup analysis of patients included in the MINDACT study
FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications
Efficacy was evaluated in Inter-B-NHL Ritux 2010 global randomised study
Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not Improve Outcomes in Early Breast Cancer
The results of the final protocol-defined analysis of the PALLAS study conducted in patients with early hormone receptor-positive, HER2-negative breast cancer
FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma
Efficacy was evaluated in KEYNOTE-716 study
Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in Terms of Invasive Disease–Free Survival
In a prespecified RxPONDER analysis, postmenopausal women with 1 to 3 positive axillary lymph nodes and a recurrence score of 0 to 25 were able to safely forgo adjuvant chemotherapy for breast cancer